1 Although this Review is very clear and comprehensive, I would like to add a new perspective to the understanding of RV failure, and the therapeutic approach to this syndrome in the particular scenario of acute pulmonary thromboembolism (APT).
Multifocal necroinflammatory alter ations (which reflect cell injury) are found in the right ventricle of patients with massive APT, and have major implications for both management and long-term prognosis.
2 These RV alterations can be the result of matrix metalloproteinase (MMP) activation and release from infiltrating leucocytes or macrophages, and increase with the s everity of the disease. Such changes to the right ventricle are associated with proportional increases in cardiac troponin I, a major b iomarker of c ardiomyocyte injury. 3 MMP activation can be prevented by the use of MMP inhibitors, including the widely used antibiotic doxycycline. 4 This intervention has been shown to protect against experimental APT-induced cardiomyocyte injury. 5 Although doxycycline slightly attenuates RV overload as a result of decreased pulmonary vascular resistance Targeting RV failure and cardiomyocyte injury in acute pulmonary thromboembolism Jose E. Tanus-Santos associated with APT, 6 evidence now exists that this drug also decreases mortality and RV deformation associated with experimental APT. 7 Moreover, because oxidative stress is a major MMP-activating factor, the antioxidant tempol has also shown protective effects against APT-induced MMP activation and cardiomyocyte injury, thus preventing increases in c irculating cardiac troponin I levels. 8 The relevance of MMP activation during APT, and the attenuation of haemo dynamic changes and cardiomyocyte injury with MMP inhibitors, might justify the use of MMP inhibitors in this critical condition. Although other agents, such as atorvastatin 9 and l-arginine 10 can also interrupt this critical pathophysiological mechanism, clinical trials are necessary to validate experimental findings indicating that MMP inhibition is a valid pharmacological strategy in the m anagement of RV failure associated with APT. 
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